Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

• Váldodahkkit: Adi Horesh (Dahkki), Rena Pollack (Dahkki), Hovav Nechushtan (Dahkki), Rivka Dresner-Pollak (Dahkki), Tzahi Neuman (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2023-04-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 express...